Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges
Open Access
Abstract
Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited therapeutic options in advanced and recurrent diseases. Advanced PSCC is typically managed with multimodal therapy, including neoadjuvant chemotherapy or chemoradiation followed by surgery; however, durable responses remain uncommon, and outcomes after recurrence are poor. Cancer vaccines represent a promising immunotherapeutic strategy, as these treatments induce tumor-specific immunity and heightened immune surveillance against penile cancer cells. While therapeutic cancer vaccines have not yet demonstrated consistent clinical efficacy as monotherapy in PSCC, their integration with complementary immune-modulating approaches, particularly immune checkpoint blockade, represents a rational strategy to enhance antitumor immunity. This review summarizes the rationale for vaccine development in PSCC, with emphasis on HPV-derived antigens, neoantigens, and emerging tumor-associated targets. We examine major vaccine platforms, including viral-vector, peptide-based, nucleic acid, and dendritic cell-based approaches. We also discuss how spatial transcriptomics, single-cell RNA sequencing, artificial intelligence-assisted antigen prediction, and nanotechnology-enhanced delivery systems may support future personalized vaccine development. Overall, therapeutic vaccines remain investigational in PSCC but may become relevant within biomarker-driven, combination-based immunotherapy strategies.Keywords
This publication has 61 references indexed in Scilit:
- The tumor microbiome and cancer immunotherapy: A systematic review of a new frontier beyond the gutBulletin du Cancer, 2025
- Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapyBiomedicine & Pharmacotherapy, 2025
- Vaccine development using artificial intelligence and machine learning: A reviewInternational Journal of Biological Macromolecules, 2024
- GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trialeClinicalMedicine, 2024
- Generative adversarial networks (GANs): Introduction, Taxonomy, Variants, Limitations, and ApplicationsMultimedia Tools and Applications, 2024
- Therapeutic Vaccination for HPV-Mediated CancersCurrent Otorhinolaryngology Reports, 2023
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related CancerJAMA Oncology, 2019
- Worldwide burden of cancer attributable to HPV by site, country and HPV typeInternational Journal of Cancer, 2017
- Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinomaWorld Journal of Urology, 2011
- Human papillomavirus DNA andp53 status in penile carcinomasInternational Journal of Cancer, 1998